对疑似异位妊娠患者使用甲氨蝶呤导致宫内妊娠暴露于甲氨蝶呤
该回顾性队列研究纳入2000至2016年因疑似异位妊娠接受甲氨蝶呤治疗的820例患者,其中692例(84.4%)缺乏异位妊娠的明确超声特征;最终16例诊断为宫内妊娠,宫内妊娠组β-hCG更高、附件包块 prevalence 更低(38% vs 74%,P=0.003)、宫腔内积液 prevalence 更高(44% vs 9%,P=0.0004)、内膜更厚(17.1±11.8 vs 9.7±5.6,P=0.04),但无任一超声参数能区分宫内妊娠。作者认为对缺乏明确异位妊娠超声特征的疑似病例,应在临床合理范围内延迟甲氨蝶呤治疗以改善诊断并避免对存活宫内妊娠误用甲氨蝶呤。
要点
- 疑似异位妊娠接受甲氨蝶呤治疗者中84.4%(692/820)缺乏异位妊娠的明确超声特征。
- 最终诊断宫内妊娠者附件包块 prevalence 更低(38% vs 74%,P=0.003)、宫腔内积液 prevalence 更高(44% vs 9%,P=0.0004)。
- 无任一超声参数能区分最终诊断为宫内妊娠的患者。
核心结论
- 大多数因疑似异位妊娠而符合药物治疗条件的患者缺乏异位妊娠的明确超声特征;对此类病例,应在临床合理范围内延迟甲氨蝶呤治疗,以改善诊断并防止对存活宫内妊娠误用甲氨蝶呤。
研究设计与样本
- 回顾性队列研究,纳入2000至2016年因疑似异位妊娠接受甲氨蝶呤治疗的全部患者820例,其中692例(84.4%)缺乏异位妊娠的明确特征,155例(22.4%)因未随访至完全消退而排除,对537例进行回顾性超声分类。
关键影像表现/征象
- 537例回顾性超声分类中,393例(73.2%)为可能异位妊娠,136例(25.3%)为不明位置妊娠,8例(1.5%)为可能宫内妊娠。
- 最终诊断宫内妊娠16例:6例来自可能异位妊娠组,9例来自不明位置妊娠组,1例来自可能宫内妊娠组。
- 最终诊断宫内妊娠者附件包块 prevalence 为38%,非宫内妊娠者为74%(P=0.003)。
- 最终诊断宫内妊娠者宫腔内积液 prevalence 为44%,非宫内妊娠者为9%(P=0.0004)。
- 最终诊断宫内妊娠者内膜厚度为17.1±11.8,非宫内妊娠者为9.7±5.6(P=0.04)。
诊断标准与关键数值
- 无任一超声参数能够区分最终诊断为宫内妊娠的患者。
- 16例宫内妊娠中1例诊断为存活妊娠,另7例为可能存活妊娠,均未选择继续妊娠。
临床应用与阅片要点
- 对疑似但未确定的异位妊娠,应在临床合理范围内延迟甲氨蝶呤治疗,以改善诊断并防止对存活宫内妊娠误用甲氨蝶呤。
- 最终诊断宫内妊娠者β-hCG值更高,附件包块 prevalence 更低,宫腔内积液 prevalence 更高,内膜更厚。
局限性
- 本研究为回顾性队列研究。
- 155例(22.4%)因未随访至完全消退而被排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To report clinical experience with methotrexate (MTX) treatment for suspected but not definite ectopic pregnancy (EP).
METHODS: This was a retrospective cohort study. All patients treated with MTX for presumed EP between 2000 and 2016 were included. Demographic, clinical, sonographic, and outcome data were collected and analyzed.
RESULTS: A total of 820 patients were treated with MTX, 692 (84.4%) of which were lacking definitive features of EP; 155 (22.4%) failed to follow up until complete resolution and were excluded. Retrospective sonographic categorization was applied to 537 patients; of those patients, 393 (73.2%) were categorized as probable EPs, 136 (25.3%) pregnancies of unknown location (PULs), and 8 (1.5%) probable intrauterine pregnancies (IUPs). Sixteen were eventually diagnosed with IUP: 6 from the probable EPs, 9 from the PULs, and 1 from the probable IUP group. Patients with final diagnosis of IUP had higher values of β-human chorionic gonadotropin as well as lower prevalence of adnexal mass (38% versus 74%; P = .003), higher prevalence of intracavitary fluid (44% versus 9%; P = .0004) and thicker endometrium (17.1 ± 11.8 versus 9.7 ± 5.6; P = .04). None of the sonographic parameters were able to distinguish patients with IUP. One patient of the 16 with IUP was diagnosed with a viable pregnancy, and 7 additional patients had a possible viable pregnancy. None of them elected to continue the pregnancy.
CONCLUSIONS: Most patients with suspected EP who are eligible for medical treatment lack definitive sonographic features of EP. Treatment with MTX in such cases should be delayed, as clinically reasonable, to improve the diagnosis and prevent inadvertent administration of MTX to patients with a viable IUP.
引用
- Fridman D, Hawkins E, Dar P, et al. Methotrexate Administration to Patients With Presumed Ectopic Pregnancy Leads to Methotrexate Exposure of Intrauterine Pregnancies. J Ultrasound Med. 2018. PMID: 30244479. doi:10.1002/jum.14751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。